Device Trial Radar · NCT07435987
Clinical Feasibility of the ARCHITECT Applicator in Cervical Cancer Brachytherapy
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Jul 22, 2026
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Erasmus Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 27, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This prospective, non-randomised, single centre, phase I trial assesses the clinical feasibility of the use of the patient-tailored ARCHITECT applicator in locally advanced cervical cancer brachytherapy.
Conditions
- Locally Advanced Cervical Cancer
- Uterine Carcinoma
Interventions
ARCHITECT applicatorDevice
Patient-tailored, 3D-printed applicator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical feasibilityTime frame: At week 2 (ARCHITECT applicator)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Erasmus Medical Center
Rotterdam, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.